Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET N 50 versus STADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET N 50 versus STADOL.
DARVOCET-N 50 vs STADOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist; it also binds to sigma receptors. Acetaminophen inhibits prostaglandin synthesis via COX-1 and COX-2, thereby reducing pain and fever.
Partial agonist at mu-opioid receptors and agonist at kappa-opioid receptors in the CNS, altering pain perception and emotional response to pain.
1 tablet (propoxyphene 50 mg, acetaminophen 300 mg) orally every 4 hours as needed for pain, not to exceed 6 tablets per day.
Butorphanol tartrate 1-2 mg IV or IM every 3-4 hours as needed for pain; alternatively, 0.5-1 mg IV every 3-4 hours. For nasal spray: 1 mg (one spray) in one nostril, may repeat in 60-90 minutes if needed; then 1 mg every 3-4 hours as needed.
None Documented
None Documented
Acetaminophen: 1.5-3 hours (therapeutic); 4-6 hours in overdose due to saturation of metabolism. Propoxyphene: 6-12 hours (parent); norpropoxyphene: 30-36 hours (active metabolite, accumulates with repeated dosing).
Terminal elimination half-life: 2.5-4 hours; clinically, prolonged in hepatic impairment (up to 10-12 hours) and elderly
Acetaminophen: renal (90-100% as metabolites within 24h; 2-4% unchanged). Propoxyphene: renal (25-30% unchanged; metabolites) and biliary/fecal (significant enterohepatic circulation).
Renal: 85-90% as unchanged drug and metabolites (primarily as glucuronide conjugates); Fecal: <10%; Biliary: minimal
Category C
Category C
Opioid Analgesic
Opioid Analgesic